In psoriasis, report shows Taltz closing in on Cosentyx

5 April 2017
pain_med_big

Two independent surveys of  200 rheumatologists and dermatologists have unveiled recent developments in clinical practice in the fields of psoriasis and psoriatic arthritis.

The report from Spherix Global Insights show increasing use of interleukin (IL)-17 agents, such as Cosentyx (secukinumab), from Swiss pharma giant Novartis (NOVN: VX), and Taltz (ixekizumab), from Eli Lilly (NYSE: LLY).

In the psoriasis market, where both drugs are approved, Taltz is making big gains and is expected to catch up to Cosentyx within the next two quarters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical